Showing 41 - 60 results of 227,870 for search '(( e fold decrease ) OR ( 10 ((((nn decrease) OR (we decrease))) OR (a decrease)) ))', query time: 1.34s Refine Results
  1. 41
  2. 42
  3. 43
  4. 44
  5. 45
  6. 46
  7. 47

    <i>Dmxl2</i> knockdown in INS-1E cells decreases glucose-induced insulin release. by Brooke Tata (633065)

    Published 2014
    “…(B) Seventy-two hours after the transfection of INS-1E cells with <i>Dmxl2-</i>siRNA, <i>Dmxl2</i> mRNA levels had decreased by 75% (error bars: SEM; from three independent experiments). …”
  8. 48
  9. 49
  10. 50
  11. 51
  12. 52
  13. 53
  14. 54

    VRK1 overexpression is seen in human breast cancer and is associated with decreased relapse-free survival. by Aye M. Mon (5714912)

    Published 2018
    “…The overall median rank of VRK1 mRNA overexpression was 947 (out of 19,273 measured genes) (p = 3.64x10<sup>-28</sup>). Data for cancer subtypes are shown in boxes numbered 1–11: 1: benign breast neoplasm (rank 6459, 1.4 fold-change, NS), 2: breast carcinoma (rank 833, 1.5 fold-change, p = 3.83x10<sup>-5</sup>), 3: breast phyllodes tumor (rank 512, 1.2 fold-change, p = 0.002), 4: ductal breast carcinoma in situ (rank 1969, 1.5 fold-change, p = 0.002), 5: invasive breast carcinoma (rank 1060, 1.6 fold-change, p = 1.28x10<sup>-5</sup>), 6: invasive ductal and invasive lobular breast carcinoma (rank 941, 1.5 fold-change, p = 6.76x10<sup>-22</sup>), 7: invasive ductal breast carcinoma (rank 613, 1.5-fold change, p = 2.71x10<sup>-71</sup>), 8: invasive lobular breast carcinoma (rank 947, 1.3 fold-change, p = 3.64x10<sup>-28</sup>), 9: medullary breast carcinoma (rank 400, 1.8 fold-change, p = 3.25x10<sup>-12</sup>), 10: mucinous breast carcinoma (rank 1932, 1.4 fold-change, p = 7.41x10<sup>-10</sup>) and 11: tubular breast carcinoma (rank 1253, 1.4 fold-change, p = 1.24x10<sup>-17</sup>). …”
  15. 55
  16. 56
  17. 57
  18. 58
  19. 59
  20. 60